ALK and anaplastic large cell lymphoma: We treated 3 ALK+ ALCL cell lines (TS, SU-DHL1 and JB6) with sublethal concentrations of crizotinib (from 10nM to 40nM) in order to inactivate NPM-ALK without affecting cell viability (Figure 1C).